While clinical performance is important in driving a product’s success in migraine, the overriding differentiation between products, and the CGRP inhibitors in particular, is market access. Despite mounting evidence for CGRP-targeting therapies as first-line prophylaxis treatment, these drugs remain on higher formulary tiers with step therapy requirements.

This Datamonitor Healthcare report contains a Disease Analysis module.